Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4287439
Max Phase: Preclinical
Molecular Formula: C28H27F2N5O6S
Molecular Weight: 599.62
Molecule Type: Small molecule
Associated Items:
ID: ALA4287439
Max Phase: Preclinical
Molecular Formula: C28H27F2N5O6S
Molecular Weight: 599.62
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1c(OCCCS(C)(=O)=O)cn2ncnc(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)c12
Standard InChI: InChI=1S/C28H27F2N5O6S/c1-17-23(40-12-3-13-42(2,38)39)15-35-24(17)25(31-16-32-35)41-22-9-8-20(14-21(22)30)34-27(37)28(10-11-28)26(36)33-19-6-4-18(29)5-7-19/h4-9,14-16H,3,10-13H2,1-2H3,(H,33,36)(H,34,37)
Standard InChI Key: KHSXMHYXEDTYDH-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 599.62 | Molecular Weight (Monoisotopic): 599.1650 | AlogP: 4.28 | #Rotatable Bonds: 11 |
Polar Surface Area: 140.99 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.14 | CX Basic pKa: | CX LogP: 3.47 | CX LogD: 3.47 |
Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.19 | Np Likeness Score: -1.41 |
1. Shi W, Qiang H, Huang D, Bi X, Huang W, Qian H.. (2018) Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2., 158 [PMID:30248654] [10.1016/j.ejmech.2018.09.050] |
Source(1):